NEOGENOMICS, INC.
FORT MYERS, FLORIDA

NeoGenomics, Inc., established on March 3, 2009, is a prominent player in the field of molecular genetics testing. This Florida-registered company, with a filing number F09000000866 and headquarter located at 9490 NeoGenomics Way, Fort Myers (33912), specializes in providing advanced diagnostic solutions across various healthcare segments, including oncology, infectious diseases, genetic disorders, cardiology, neuroscience, and more. NeoGenomics is incorporated as a Florida Corporation classified under the 'For Profit' model with the status of a domestic entity headquartered outside of Florida but maintaining significant operations within the state. According to the latest annual report submitted on April 8, 2024, NeoGenomics demonstrates robust growth and innovation in genetic and molecular testing services. The company is led by influential directors and corporate officers including Stephen Kanovsky and Michael A. Kelly as Directors. It operates a comprehensive array of services across its headquarters in Fort Myers and with an extensive network facilitating state-of-the-art laboratory testing capabilities. NeoGenomics prides itself on providing high-quality, rapid-turnaround diagnostic testing to healthcare providers, empowering them to make informed clinical decisions timely. Its mission is fundamentally anchored to advancing life-saving genetic testing technologies that improve patient outcomes globally. Staying at the forefront of innovation and adhering to stringent quality control standards, NeoGenomics holds a Federal Employer Identification Number (FEI) of 74-2897368. Patients and healthcare professionals alike can explore more about their service offerings through the company's official website, neogenomics.com.